CO2019000643A2 - Formulaciones gastrorretentivas orales y usos de las mismas - Google Patents

Formulaciones gastrorretentivas orales y usos de las mismas

Info

Publication number
CO2019000643A2
CO2019000643A2 CONC2019/0000643A CO2019000643A CO2019000643A2 CO 2019000643 A2 CO2019000643 A2 CO 2019000643A2 CO 2019000643 A CO2019000643 A CO 2019000643A CO 2019000643 A2 CO2019000643 A2 CO 2019000643A2
Authority
CO
Colombia
Prior art keywords
gastro
administration
retentive formulations
retentive
oral gastro
Prior art date
Application number
CONC2019/0000643A
Other languages
English (en)
Spanish (es)
Inventor
Nadav Navon
Ronny Reinberg
Yochai Yakovson
Original Assignee
Intec Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59388117&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019000643(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intec Pharma Ltd filed Critical Intec Pharma Ltd
Publication of CO2019000643A2 publication Critical patent/CO2019000643A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CONC2019/0000643A 2016-07-11 2019-01-23 Formulaciones gastrorretentivas orales y usos de las mismas CO2019000643A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662360744P 2016-07-11 2016-07-11
PCT/IL2017/050783 WO2018011798A1 (en) 2016-07-11 2017-07-11 Oral gastroretentive formulations and uses thereof

Publications (1)

Publication Number Publication Date
CO2019000643A2 true CO2019000643A2 (es) 2019-04-30

Family

ID=59388117

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0000643A CO2019000643A2 (es) 2016-07-11 2019-01-23 Formulaciones gastrorretentivas orales y usos de las mismas

Country Status (17)

Country Link
US (1) US20190224118A1 (cg-RX-API-DMAC10.html)
EP (1) EP3481371A1 (cg-RX-API-DMAC10.html)
JP (1) JP2019527208A (cg-RX-API-DMAC10.html)
KR (1) KR20190026799A (cg-RX-API-DMAC10.html)
CN (1) CN109414403A (cg-RX-API-DMAC10.html)
AU (1) AU2017296351A1 (cg-RX-API-DMAC10.html)
BR (1) BR112018077541A2 (cg-RX-API-DMAC10.html)
CA (1) CA3027700A1 (cg-RX-API-DMAC10.html)
CO (1) CO2019000643A2 (cg-RX-API-DMAC10.html)
IL (1) IL264065A (cg-RX-API-DMAC10.html)
MX (1) MX2019000348A (cg-RX-API-DMAC10.html)
NZ (1) NZ750422A (cg-RX-API-DMAC10.html)
PH (1) PH12019500061A1 (cg-RX-API-DMAC10.html)
RU (1) RU2019103297A (cg-RX-API-DMAC10.html)
SG (2) SG10202100182TA (cg-RX-API-DMAC10.html)
WO (1) WO2018011798A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201900275B (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018152334A1 (en) * 2017-02-15 2018-08-23 Molecular Infusions, Llc Formulations
BR102018002843A2 (pt) * 2018-02-09 2019-08-27 Prati, Donaduzzi & Cia Ltda composição farmacêutica e uso da mesma
WO2020037410A1 (en) * 2018-08-20 2020-02-27 Hexo Operations Inc. Cannabis-infused product with enhanced cannabinoid profile user experience
GB2584341B (en) * 2019-05-31 2023-03-01 Gw Res Ltd Cannabinoid formulations
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
JP2022551730A (ja) 2019-10-14 2022-12-13 パイク セラピューティクス，インコーポレイテッド カンナビジオールの経皮送達
US20210177740A1 (en) * 2019-12-11 2021-06-17 Joel Studin Transpore delivery of cannabinoid and uses thereof
EP4084790A1 (en) * 2020-01-02 2022-11-09 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Floating drug delivery systems comprising cannabinoids
CA3217137A1 (en) 2021-04-29 2022-11-03 Christopher Adair Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
WO2023272335A1 (en) * 2021-06-30 2023-01-05 Emyria Cannabidiol formulation comprising a matrix pellet forming excipient
CN114796142A (zh) * 2022-04-08 2022-07-29 黄山学院 萘普生胃漂浮片及其制备方法
TW202430130A (zh) * 2022-10-18 2024-08-01 大陸商南京三迭紀醫藥科技有限公司 用於胃滯留的口服藥物劑型
CN117224522B (zh) * 2023-11-15 2024-02-23 北京协和药厂有限公司 药物组合物及其制备方法、药物制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03163011A (ja) * 1989-08-31 1991-07-15 Yamanouchi Pharmaceut Co Ltd 胃内滞留デバイス
IL133196A0 (en) * 1999-11-29 2001-03-19 Yissum Res Dev Co Gastroretentive controlled release pharmaceutical dosage forms
US10004684B2 (en) * 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
US9265724B2 (en) * 2005-11-07 2016-02-23 Ram B. Murty Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
PT1903866E (pt) 2005-11-07 2016-06-09 Murty Pharmaceuticals Inc Distribuição melhorada de tetra-hidrocanabinol
DK2997953T3 (en) 2006-01-18 2019-04-15 Intec Pharma Ltd ADMINISTRATION ORAL ADMINISTRATION
DK2276473T3 (en) * 2008-04-18 2017-01-09 Intec Pharma Ltd GASTRORETENTIV drug TO carbidopa / levodopa
WO2010064139A2 (en) * 2008-12-04 2010-06-10 Intec Pharma Ltd. Zaleplon gastroretentive drug delivery system
WO2011048494A2 (en) 2009-10-19 2011-04-28 Intec Pharma Ltd. Novel gastroretentive dosage forms of poorly soluble drugs
US20140017303A1 (en) * 2010-11-01 2014-01-16 Intec Pharma Ltd. Accordion pill comprising levodopa for an improved treatment of parkinson's disease symptoms
US8808734B2 (en) 2011-07-11 2014-08-19 Full Spectrum Laboratories Limited Cannabinoid formulations
KR20160002709A (ko) * 2013-02-12 2016-01-08 코버스 파마수티컬스, 아이엔씨. 초고순도 테트라하이드로카나비놀-11-오익산
WO2015025312A1 (en) 2013-08-21 2015-02-26 Cannabics Pharmaceuticals Inc Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof

Also Published As

Publication number Publication date
JP2019527208A (ja) 2019-09-26
CA3027700A1 (en) 2018-01-18
ZA201900275B (en) 2020-05-27
NZ750422A (en) 2021-10-29
BR112018077541A2 (pt) 2019-04-30
SG11201811209QA (en) 2019-01-30
WO2018011798A1 (en) 2018-01-18
PH12019500061A1 (en) 2019-10-14
MX2019000348A (es) 2019-03-28
RU2019103297A3 (cg-RX-API-DMAC10.html) 2020-11-06
SG10202100182TA (en) 2021-02-25
AU2017296351A1 (en) 2019-02-28
EP3481371A1 (en) 2019-05-15
CN109414403A (zh) 2019-03-01
KR20190026799A (ko) 2019-03-13
RU2019103297A (ru) 2020-08-11
IL264065A (en) 2019-01-31
US20190224118A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
BR112018077541A2 (pt) formulações orais gastrorretentivas e usos das mesmas
IL275704A (en) Pharmaceutical formulation for oral administration containing cannabinoids and poloxamer
CL2018000705A1 (es) Método de cristalización y biodisponibilidad
MX2018010032A (es) Formulaciones de antagonista de il-6 y sus usos.
CO2021013677A2 (es) Proceso para la fabricación de extractos bacterianos estables y su uso como fármacos
MX375286B (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
MX2021010359A (es) Una composicion farmaceutica para reducir la grasa localizada y sus usos.
BR112015018087A8 (pt) composto, composição farmacêutica e uso
ES2850277R1 (es) Composiciones de administración farmacéutica y usos de las mismas
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
CO2017002682A2 (es) Composiciones y métodos para recubrimientos cannabinoides para uso en la entrega de fármacos
MX2019001318A (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
CO2018012506A2 (es) Composiciones farmacéuticas y regímenes de dosificación para el uso clínico de anticuerpos contra el antígeno 2 de las células dendríticas de la sangre
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
MX2023006235A (es) Composiciones para administracion de farmacos y metodos de uso de las mismas.
IT201800001301A1 (it) Formulazioni in gel per la somministrazione orale di farmaci, in particolare nei pazienti disfagici
PE20181369A1 (es) Suspensiones orales acuosas fisica y quimicamente estables de givinostat
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
AR108233A1 (es) Composiciones farmacéuticas orales de nicotinamida
DK4027973T3 (da) Formuleringer til lægemiddeladministration
MX368735B (es) (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.
IL283405A (en) Formulations, methods, kits and dosage forms to improve the stability of an active medicinal component
MX2018012223A (es) Formulaciones liquidas de fosfaplatino.
EP4042999C0 (en) SOLID ORAL MEDICATION RECEIVING DEVICE, AND ORAL ADMINISTRATION DEVICE INCLUDING IT